This time, Jinyu medicine violated public anger. When the whole nation was struggling against epidemic diseases, Jinyu medicine, the largest testing institution in China, was caused by the local staff who caused the COVID-19 to spread or spread dangerous behavior. Although the current investigation is inconclusive, in any case, we can't get rid of the word "benefit". The concentrated demand for nucleic acid testing has promoted the performance of Jinyu medicine and the stock price has soared. The institutions participating in this capital feast have doubled their profits. Employee crime What kind of dangerous behavior has Henan implemented in the COVID-19 test? It's still a mystery. On the 12 day, the Xuchang police announced that Zhang Dong, the head of the gold area of Zhengzhou, a subsidiary of 603882.SH, was in violation of the provisions of the infectious disease prevention and control law and implemented the act of causing COVID-19 to spread or spread serious risks. On the 10th, he was placed on file for investigation on suspicion of a criminal crime and compulsory measures were taken. According to the statement of Jinyu medicine, on January 2, Zhengzhou Jinyu received a notice from relevant departments in Yuzhou asking to participate in the local epidemic prevention and control, and six staff members including Zhang moudong went there. During this period, it mainly provided on-site support in various villages and towns, including system software training and processing, specimen transport vehicle scheduling, consumables transportation and distribution, etc. What Zhang did in the end was not clear to the police and Jinyu, and the outside world talked about it one after another. There are rumors of "actively spreading virus", "losing samples", "forging data" and "concealing data", which Jinyu medicine denies through official wechat. It is understood that after the outbreak of this round of epidemic in Yuzhou, Henan Province, the relevant testing work is provided by Jinyu. The residents participating in the first five rounds of testing need to use a small program called "Jinyu service". The applet can complete the registration record of personal data and the query of test results. Recently, the local government suddenly announced that the applet was disabled, or it was related to Zhang moudong's behavior. Jinyu medicine said it would cooperate with the police to investigate the incident and publish the investigation results to the public. Previously, some institutions had problems in the detection of the epidemic. In January last year, Jinan Huaxi medicine did not complete the testing of all samples, that is, it fed back to the relevant departments of Longyao county that the results were all "negative", and the relevant staff were taken criminal coercive measures. Performance soared Jinyu medicine was originally a school run enterprise of Guangzhou Medical College. After restructuring, Liang Yaoming, who graduated from the school in clinical medicine and worked in the school for many years, became the actual controller of the company and entered the field of third-party testing on a large scale. According to the data, in 2019, the total income of China's medical and health institutions reached 4.64 trillion, the income from medical testing accounted for about 10%, the total amount was 464 billion yuan, and the third-party testing accounted for about 8%, with a total scale of about 37 billion yuan. In recent years, the third-party testing market has shown an overall growth trend, and the industry penetration rate has increased from 5% in 2015 to 8% in 2020. However, compared with the 35-67% market share of developed countries such as the United States, Europe and Japan, there is still much room for growth. Jinyu medicine is the largest third-party medical testing institution in China. It provides 2800 testing project outsourcing and scientific research and technical services for 23000 medical institutions in China. It has established 38 central laboratories in 31 provinces and cities in China and Hong Kong. Jinyu medicine has deep contacts in the industry, and a luxury consulting team is composed of 7 academicians such as Zhong Nanshan and Zeng Yitao. In 2017, the company landed on the main board of Shanghai Stock Exchange, and its revenue scale and performance continued to improve, becoming a white horse stock in the industry. Especially under the epidemic situation in 2020, the company has been involved in nucleic acid detection services in more than 30 provinces and cities across the country, with a cumulative detection volume of more than 32 million people, accounting for about 1 / 10 of the national nucleic acid detection volume in that year, becoming the single organization with the largest nucleic acid detection volume in the world. Driven by the centralized demand for nucleic acid detection, the company's revenue increased by 56.45% to 8.244 billion yuan that year; The net profit attributable to the parent company increased by 275.24% to RMB 1.51 billion. Last year, the epidemic situation was repeated, and the demand for nucleic acid detection continued. In the first three quarters, the company's revenue and performance exceeded that of the whole year of last year. An insider in the medical testing industry disclosed to zebra consumer that recently, his enterprise has received new business from many places. Previously, nucleic acid testing services in these places were provided by Jinyu medicine. Capital feast If it is not for the nucleic acid detection needs brought by COVID-19, the three party testing organizations such as Jinyu medicine are hard to get explosive growth. They are hidden behind the medical institutions and will not be well known to the public and ordinary investors. In fact, in the first two years of listing, the highest share price of Jinyu medicine stayed at 47.15 yuan at the beginning of listing. In October 2018, it once fell to a historical low of 15.28 yuan, and the market value fell from more than 20 billion yuan to less than 7 billion yuan. Subsequently, the company's share price hit the bottom and rebounded, and remained at a stage high after 2019. COVID-19 triggered the market's concern about the related stocks. After the release of golden field medical journal in 2020, the company's share price continued to rush ahead, breaking through 100 yuan mark. During this period, it adjusted slightly, then rushed upward again, reaching a historical high of 178.55 yuan in January 25, 2021, and its market value exceeded 80 billion yuan. At the end of December 2020 and June 2021, 539 and 606 funds participated in the feast respectively. Looking at the continuous rise of stock prices, institutional investors before the company's listing are obviously unwilling to miss this wave of market and intensively announce the reduction of holdings. According to incomplete statistics of zebra consumption, from the third quarter of 2019 to 2021, several institutions reduced their holdings and cashed out nearly 7 billion yuan, earning dozens of times of income. Company executives also joined the reduction army. In June last year, deputy general managers Wang linglai and Yu Shihui almost stepped on the high point, reducing 41900 shares and 10000 shares with 138.556-149.39 yuan and 143.075-145.99 yuan respectively, cashing out 6039400 yuan and 1449100 yuan. Among them, Wang also reduced his holdings of 650 shares due to operational errors. In March 2021, Liang Yaoming, the actual controller of the company, subscribed for the company's non-public offering shares at 48.02 yuan / share. With the rise of the company's share price, the company's profit was nearly three times. On the 12th and 13th, affected by the factors related to criminal cases of employees, Jinyu medicine fell 5.79% and 5.87% for two consecutive days. The latest share price was 85.66 yuan and the total market value was 39.8 billion yuan. (Xinhua News Agency)